464 related articles for article (PubMed ID: 28267244)
1. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D; Hatake K; Kinoshita T; Fukuhara N; Choi I; Taniwaki M; Ando K; Terui Y; Higuchi Y; Onishi Y; Abe Y; Kobayashi T; Shirasugi Y; Tobinai K
Cancer Sci; 2017 May; 108(5):1007-1012. PubMed ID: 28267244
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
4. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D; Terui Y; Yamamoto K; Fukuhara N; Choi I; Kuroda J; Ando K; Hattori A; Tobinai K
Jpn J Clin Oncol; 2020 Oct; 50(11):1265-1273. PubMed ID: 32776097
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Lisano J; Wen R; Akyol A; Moskowitz AJ
Blood Adv; 2023 Sep; 7(18):5272-5280. PubMed ID: 37352266
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM; Bröckelmann PJ; von Keudell G; Lee HJ; Santoro A; Zinzani PL; Collins GP; Cohen JB; de Boer JP; Kuruvilla J; Savage KJ; Trněný M; Provencio M; Jäger U; Willenbacher W; Wen R; Akyol A; Mikita-Geoffroy J; Shipp MA; Engert A; Armand P
Blood Adv; 2023 Oct; 7(20):6266-6274. PubMed ID: 37530622
[TBL] [Abstract][Full Text] [Related]
16. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV; Lepik KV; Volkov NP; Kotselyabina PV; Borzenkova ES; Popova MO; Beynarovich AV; Baykov VV; Kozlov AV; Moiseev IS; Mikhailova NB; Kulagin AD
Int J Clin Oncol; 2022 Mar; 27(3):626-632. PubMed ID: 34826011
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
19. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
